Vasileiou

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Retrieved on: 
Monday, January 8, 2024
Baylor University, Baylor College of Medicine, Neoplasm, Risk, Leukapheresis, IND, MRD, DLBCL, FDA, Drug discovery, Service provider, Disease, Trial of the century, PCR, Therapy, Marker, Natural history, ARTEMIS, Vasileiou, Mutagenesis, Pancreatic cancer, Press release, Chong, Growth, HSCT, CD19, Patient, Acute myeloid leukemia, Safety, AML, Bone marrow, Food and Drug Administration, Female, APOLLO, Pharmaceutical industry

HOUSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. In addition, the Company reported a clinical update on the Phase 2 ARTEMIS study investigating MT-401, a multiTAA-specific T cell product, for the treatment of patients with acute myeloid leukemia (AML).

Key Points: 
  • The TACTAL study enrolled patients with Hodgkin’s and non-Hodgkin’s lymphoma and demonstrated clinical safety and efficacy with durable clinical responses for 6 years (Vasileiou et al, J Clin Oncol, 2021).
  • Today, Marker is providing a clinical update on the Phase 2 ARTEMIS clinical study (clinicaltrials.gov identifier: NCT04511130), and the direction it will pursue.
  • “We are encouraged by the clinical observations in patients with MRD in our AML study,” said Juan Vera, M.D., President and CEO of Marker Therapeutics.
  • Marker has secured non-dilutive funding to support the clinical investigation of a ready for use MT-401 product in patients with AML.

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Retrieved on: 
Monday, June 12, 2023
Lymphoma, Marker, Antigen, CD19, Vasileiou, Lymphoid leukemia, The New England Journal of Medicine, Clinical trial, Hope, Research, APOLLO, Administration, CAR, HIV disease progression rates, Patient, Standard of care, Canadian Aviation Regulations, Observation, Baylor College of Medicine, Growth, Toxic epidermal necrolysis, Neoplasm, Therapy, Safety, Bone marrow, Vaccine, Pharmaceutical industry

The primary objective of this exploratory Phase 1 clinical trial is to evaluate the optimum dose, safety, and preliminary efficacy of MT-601 in patients with various lymphoma subtypes.

Key Points: 
  • The primary objective of this exploratory Phase 1 clinical trial is to evaluate the optimum dose, safety, and preliminary efficacy of MT-601 in patients with various lymphoma subtypes.
  • Data from the APOLLO trial will guide Marker Therapeutics on the future development of MT-601.
  • Under the APOLLO trial, eight clinical sites across the United States will cumulatively enroll up to 30 patients during the dose escalation phase.
  • We are committed to diligently monitoring and analyzing the data from this Phase 1 clinical trial to ensure we continue making informed decisions that prioritize patient safety and therapeutic effectiveness," concluded Dr. Vera.

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Retrieved on: 
Wednesday, May 31, 2023
Lymphoma, Baylor, Antigen, Marker, Probability, CD19, Vasileiou, Chong, TAA, Neoplasm, The New England Journal of Medicine, Drug discovery, Clinical trial, SSX2, PRAME, CAR, Patient, Standard of care, WT-1, Growth, FDA, Therapy, IND, Safety, Bone marrow, Vaccine, Pharmaceutical industry, Survivin, Research

The multiTAA-specific T cell product used in the TACTAL study was directed against five antigens and showed more durable clinical responses.

Key Points: 
  • The multiTAA-specific T cell product used in the TACTAL study was directed against five antigens and showed more durable clinical responses.
  • Prior to starting the clinical trial Marker assessed the killing capacity of MT-601 in vitro in a lymphoma cell line and demonstrated that MT-601 kills lymphoma cells regardless of their CD19 expression levels.
  • Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited growth of lymphoma cells as well as the growth of CD19 CAR resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics.
  • While the CAR T cells significantly controlled lymphoma cell growth, we observed that 3 weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells that were resistant to CD19 CAR T cell administration started to grow.